Groupe la Francaise Sells 49,250 Shares of Qiagen N.V. $QGEN

Groupe la Francaise lessened its holdings in Qiagen N.V. (NYSE:QGEN) by 37.0% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 83,911 shares of the company’s stock after selling 49,250 shares during the period. Groupe la Francaise’s holdings in Qiagen were worth $3,252,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Price T Rowe Associates Inc. MD increased its position in shares of Qiagen by 12.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock valued at $379,072,000 after acquiring an additional 906,589 shares during the last quarter. Deutsche Bank AG boosted its position in Qiagen by 9.7% in the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after purchasing an additional 697,342 shares during the last quarter. Amundi grew its stake in Qiagen by 12.4% in the 1st quarter. Amundi now owns 4,757,681 shares of the company’s stock valued at $190,498,000 after purchasing an additional 524,959 shares during the period. Boston Partners purchased a new stake in shares of Qiagen during the 3rd quarter valued at $179,450,000. Finally, Norges Bank purchased a new stake in shares of Qiagen during the 4th quarter valued at $166,500,000. 70.00% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on QGEN. Barclays set a $40.00 price target on shares of Qiagen and gave the stock an “equal weight” rating in a report on Friday, August 7th. Berenberg Bank set a $45.50 target price on shares of Qiagen and gave the company a “hold” rating in a research report on Tuesday, July 14th. Kepler Capital Markets set a $38.60 price target on shares of Qiagen and gave the stock a “hold” rating in a research note on Thursday, June 25th. TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. upped their price objective on Qiagen from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, Qiagen has an average rating of “Hold” and a consensus target price of $43.93.

Qiagen Stock Performance

Shares of QGEN stock opened at $43.36 on Tuesday. The stock has a market capitalization of $8.94 billion, a P/E ratio of 22.22, a PEG ratio of 4.33 and a beta of 0.63. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. The firm’s 50 day moving average is $41.98 and its 200 day moving average is $40.30. Qiagen N.V. has a 12 month low of $32.53 and a 12 month high of $57.81.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The company had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. During the same period last year, the firm earned $0.60 EPS. Qiagen’s revenue for the quarter was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, sell-side analysts anticipate that Qiagen N.V. will post 2.43 earnings per share for the current year.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.